AIMS/HYPOTHESIS: Few studies have explored the epidemiology of beta cell loss in youth with diabetes. This report describes the evolution and major determinants of beta cell function, assessed by fasting C-peptide (FCP), in the SEARCH for Diabetes in Youth study. METHODS: Participants were 1,277 youth with diabetes (948 positive for diabetes autoantibodies [DAs] and 329 negative for DAs), diagnosed when aged <20 years, who were followed from a median of 8 months post diagnosis, for approximately 30 months. We modelled the relationship between rate of change in log FCP and determinants of interest using repeated measures general linear models. RESULTS: Among DA-positive youth, there was a progressive decline in beta cell function of 4% per month, independent of demographics (age, sex, race/ethnicity), genetic susceptibility to autoimmunity (HLA risk), HbA(1c) and BMI z score, or presence of insulin resistance. Among DA-negative youth, there was marked heterogeneity in beta cell loss, reflecting an aetiologically mixed group. This group likely includes youths with undetected autoimmunity (whose decline is similar to that of DA-positive youth) and youth with non-autoimmune, insulin-resistant diabetes, with limited decline (~0.7% per month). CONCLUSIONS/ INTERPRETATION: SEARCH provides unique estimates of beta cell function decline in a large sample of youth with diabetes, indicating that autoimmunity is the major contributor. These data contribute to a better understanding of clinical evolution of beta cell function in youth with diabetes, provide strong support for the aetiological classification of diabetes type and may inform tertiary prevention efforts targeted at high-risk groups.
AIMS/HYPOTHESIS: Few studies have explored the epidemiology of beta cell loss in youth with diabetes. This report describes the evolution and major determinants of beta cell function, assessed by fasting C-peptide (FCP), in the SEARCH for Diabetes in Youth study. METHODS:Participants were 1,277 youth with diabetes (948 positive for diabetes autoantibodies [DAs] and 329 negative for DAs), diagnosed when aged <20 years, who were followed from a median of 8 months post diagnosis, for approximately 30 months. We modelled the relationship between rate of change in log FCP and determinants of interest using repeated measures general linear models. RESULTS: Among DA-positive youth, there was a progressive decline in beta cell function of 4% per month, independent of demographics (age, sex, race/ethnicity), genetic susceptibility to autoimmunity (HLA risk), HbA(1c) and BMI z score, or presence of insulin resistance. Among DA-negative youth, there was marked heterogeneity in beta cell loss, reflecting an aetiologically mixed group. This group likely includes youths with undetected autoimmunity (whose decline is similar to that of DA-positive youth) and youth with non-autoimmune, insulin-resistant diabetes, with limited decline (~0.7% per month). CONCLUSIONS/ INTERPRETATION: SEARCH provides unique estimates of beta cell function decline in a large sample of youth with diabetes, indicating that autoimmunity is the major contributor. These data contribute to a better understanding of clinical evolution of beta cell function in youth with diabetes, provide strong support for the aetiological classification of diabetes type and may inform tertiary prevention efforts targeted at high-risk groups.
Authors: Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: D Dabelea; R B D'Agostino; C C Mason; N West; R F Hamman; E J Mayer-Davis; D Maahs; G Klingensmith; W C Knowler; K Nadeau Journal: Diabetologia Date: 2010-10-01 Impact factor: 10.122
Authors: Deborah D Ingram; Jennifer D Parker; Nathaniel Schenker; James A Weed; Brady Hamilton; Elizabeth Arias; Jennifer H Madans Journal: Vital Health Stat 2 Date: 2003-09
Authors: R Bonfanti; E Bazzigaluppi; G Calori; M C Riva; M Viscardi; E Bognetti; F Meschi; E Bosi; G Chiumello; E Bonifacio Journal: Diabet Med Date: 1998-10 Impact factor: 4.359
Authors: Dana Dabelea; Catherine Pihoker; Jennifer W Talton; Ralph B D'Agostino; Wilfred Fujimoto; Georgeanna J Klingensmith; Jean M Lawrence; Barbara Linder; Santica M Marcovina; Elizabeth J Mayer-Davis; Giuseppina Imperatore; Lawrence M Dolan Journal: Diabetes Care Date: 2011-06-02 Impact factor: 19.112
Authors: Carla J Greenbaum; Andrea M Anderson; Lawrence M Dolan; Elizabeth J Mayer-Davis; Dana Dabelea; Giuseppina Imperatore; Santica Marcovina; Catherine Pihoker Journal: Diabetes Care Date: 2009-07-08 Impact factor: 17.152
Authors: Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler Journal: Diabetes Care Date: 2008-07-23 Impact factor: 17.152
Authors: Beverley M Shields; Timothy J McDonald; Richard Oram; Anita Hill; Michelle Hudson; Pia Leete; Ewan R Pearson; Sarah J Richardson; Noel G Morgan; Andrew T Hattersley Journal: Diabetes Care Date: 2018-06-07 Impact factor: 19.112
Authors: Richard A Oram; Timothy J McDonald; Beverley M Shields; Michelle M Hudson; Maggie H Shepherd; Suzanne Hammersley; Ewan R Pearson; Andrew T Hattersley Journal: Diabetes Care Date: 2014-12-17 Impact factor: 19.112
Authors: Elizabeth J Mayer-Davis; Dana Dabelea; Jamie L Crandell; Tessa Crume; Ralph B D'Agostino; Lawrence Dolan; Irena B King; Jean M Lawrence; Jill M Norris; Catherine Pihoker; Natalie The Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112